13 research outputs found
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
This review presents an overview of the most recent data using the novel agents thalidomide, bortezomib, and lenalidomide in the treatment of multiple myeloma and summarizes European treatment practices incorporating these novel agents
European Perspective on Multiple Myeloma Treatment Strategies in 2014
The treatment of multiple myeloma has undergone significant changes and
has resulted in the achievement of molecular remissions, the
prolongation of remission duration, and extended survival becoming
realistic goals, with a cure being possible in a small but growing
number of patients. In addition, nowadays it is possible to categorize
patients more precisely into different risk groups, thus allowing the
evaluation of therapies in different settings and enabling a better
comparison of results across trials. Here, we review the evidence from
clinical studies, which forms the basis for our recommendations for the
management of patients with myeloma. Treatment approaches depend on
“fitness,” with chronological age still being an important
discriminator for selecting therapy. In younger, fit patients, a short
three drug-based induction treatment followed by autologous stem cell
transplantation (ASCT) remains the preferred option. Consolidation and
maintenance therapy are attractive strategies not yet approved by the
European Medicines Agency, and a decision regarding post-ASCT therapy
should only be made after detailed discussion of the pros and cons with
the individual patient. Two-and three-drug combinations are recommended
for patients not eligible for transplantation. Treatment should be
administered for at least nine cycles, although different durations of
initial therapy have only rarely been compared so far. Comorbidity and
frailty should be thoroughly assessed in elderly patients, and treatment
must be adapted to individual needs, carefully selecting appropriate
drugs and doses. A substantial number of new drugs and novel drug
classes in early clinical development have shown promising activity.
Their introduction into clinical practice will most likely further
improve treatment results. The Oncologist 2014; 19: 829-84
European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses
The management of multiple myeloma has undergone profound changes over
the recent past as a result of advances in our understanding of the
disease biology as well as improvements in treatment and supportive care
strategies. Notably, recent years have seen a surge in studies
incorporating the novel agents thalidomide, bortezomib, and lenalidomide
into treatment for different disease stages and across different patient
groups. This article presents an update to a previous review of European
treatment practices and is based on discussions during an expert meeting
that was convened to review novel agent data published or presented at
medical meetings until the end of 2011 and to assess their impact on
treatment strategies. The Oncologist 2012;17:592-60
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
The treatment of multiple myeloma (MM) has undergone significant
developments in recent years. The availability of the novel agents
thalidomide, bortezomib, and lenalidomide has expanded treatment options
and has improved the outcome of patients with MM. Following the
introduction of these agents in the relapsed/refractory setting, they
are also undergoing investigation in the initial treatment of MM. A
number of phase III trials have demonstrated the efficacy of novel agent
combinations in the transplant and nontransplant settings, and based on
these results standard induction regimens are being challenged and
replaced. In the transplant setting, a number of newer induction
regimens are now available that have been shown to be superior to the
vincristine, doxorubicin, and dexamethasone regimen. Similarly, in the
front-line treatment of patients not eligible for transplantation,
regimens incorporating novel agents have been found to be superior to
the traditional melphalan plus prednisone regimen. Importantly, some of
the novel agents appear to be active in patients with high-risk disease,
such as adverse cytogenetic features, and certain comorbidities, such as
renal impairment. This review presents an overview of the most recent
data with these novel agents and summarizes European treatment practices
incorporating the novel agents. The Oncologist 2010; 15: 6-2
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
The arrival of the novel agents thalidomide, bortezomib, and
lenalidomide has significantly changed our approach to the management of
multiple myeloma and, importantly, patient outcomes have improved. These
agents have been investigated intensively in different treatment
settings, providing us with data to make evidence-based decisions
regarding the optimal management of patients. This review is an update
to a previous summary of European treatment practices that examines new
data that have been published or presented at congresses up to the end
of 2010 and assesses their impact on treatment practices. The Oncologist
2011;16:388-40
European perspective on multiple myeloma treatment strategies in 2014
The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients. In addition, nowadays it is possible to categorize patients more precisely into different risk groups, thus allowing the evaluation of therapies in different settings and enabling a better comparison of results across trials. Here, we review the evidence from clinical studies, which forms the basis for our recommendations for the management of patients with myeloma. Treatment approaches depend on "fitness," with chronological age still being an important discriminator for selecting therapy. In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option. Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency, and a decision regarding post-ASCT therapy should only be made after detailed discussion of the pros and cons with the individual patient. Two- and three-drug combinations are recommended for patients not eligible for transplantation. Treatment should be administered for at least nine cycles, although different durations of initial therapy have only rarely been compared so far. Comorbidity and frailty should be thoroughly assessed in elderly patients, and treatment must be adapted to individual needs, carefully selecting appropriate drugs and doses. A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results
European perspective on multiple myeloma treatment strategies: Update following recent congresses
The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies